ClinicalTrials.gg
TerminatedNCT00476996SCRIPTUpdated Aug 12, 2019Results posted

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

A Phase 3 interventional study of Leflunomide and Methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated at 266 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Why this study was terminated
Recruitment was fully completed for this study; however, the study was terminated during conduct after the primary endpoint analysis was completed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
836
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
11th of 141
836 · median 132
Started
2007
with 14 others
Phase 3
85 of 219
none open now
Registered
33rd of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 85 in phase 3, and was the 33rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26. All patients will receive stable doses of either concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive additional DMARDs. The treatment period is planned for 48 weeks (until primary analysis) and then participants will enter the open label phase until the drug is commercialized. Target sample size is 1000.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • RA
  • SCRIPT
  • anti-CD20
  • CD20
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥ 18 years of age
  • Rheumatoid arthritis for at least 3 months
  • Inadequate response to previous or current treatment with at least one anti-TNF-alpha agent
  • Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for the last 4 weeks
  • Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline.
  • CRP ≥ 0.6 mg/dL using a high-sensitivity assay.
  • Positive rheumatoid factor or positive anti-CCP antibody or both.

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease or inflammatory joint disease, other than RA
  • Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
836 participants (actual)

Study arms

  • Experimental
    Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy

    Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD

    Drug: Leflunomide · Drug: Methotrexate · Drug: Ocrelizumab

  • Experimental
    Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy

    Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD

    Drug: Leflunomide · Drug: Methotrexate · Drug: Ocrelizumab

  • Placebo comparator
    Placebo x 2 IV + Non-Biologic DMARD Therapy

    Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD

    Drug: Leflunomide · Drug: Methotrexate · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With American College of Rheumatology 20 (ACR20) Responses

    ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale \[VAS\]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.

    Time frame: Weeks 24 and 48

Secondary outcomes

  1. Percentage of Participants With a Major Clinical Response

    Major clinical response was defined as achieving an ACR70 response and maintaining this response for a consecutive period of at least 6 months.

    Time frame: Week 48

  2. Percentage of Participants Achieving Disease Activity Score (DAS28) Remission

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Weeks 24 and 48

  3. Change in DAS28 From Baseline

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

    Time frame: Weeks 24 and 48

  4. Percentage of Participants With EULAR Response Rates of Good/ Moderate

    The EULAR response rate was based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.

    Time frame: Weeks 24 and 48

  5. Percentage of Participants Achieving an ACR50 Response

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, Health Assessment Questionnaire with Disability Index (HAQ-DI), and C-Reactive Protein (CRP).

    Time frame: Weeks 24 and 48

  6. Percentage of Participants Achieving an ACR70 Response

    ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, HAQ-DI and CRP.

    Time frame: Weeks 24 and 48

  7. Percentage of Participants With a Reduction in the HAQ-DI Score

    Health Assessment Questionnaire - Disability Index (HAQ-DI): The Stanford Health Assessment Questionnaire disability index is a patient reported questionnaire specific for RA. It consists of 20 questions referring to eight component. Reduction in the HAQ-DI score of 0.25 units from baseline to weeks 24 and 48 represented a minimal clinically relevant improvement.

    Time frame: Weeks 24 and 48

07

Results

Posted Aug 12, 2019

Participant flow

Participants were recruited across 25 countries.

Blinded Treatment Phase (up to Week 48)
Participant flow — Blinded Treatment Phase (up to Week 48)
MilestonePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE)
Started2772772820
Completed2052222370
Not completed7255450
Withdrew: Withdrawal by subject12770
Withdrew: Protocol violation1300
Withdrew: Early termination of the study2420210
Withdrew: Non-compliance with study drug0200
Withdrew: Lost to follow-up0430
Withdrew: Lack of efficacy22560
Withdrew: Death2110
Withdrew: Adverse event111370
OLE Phase (From Week 48)
Participant flow — OLE Phase (From Week 48)
MilestonePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE)
Started000664
Completed0000
Not completed000664
Withdrew: Withdrawal by subject00050
Withdrew: Adverse event0008
Withdrew: Death0007
Withdrew: Lack of efficacy00013
Withdrew: Lost to follow-up0004
Withdrew: Non-compliance with study drug0004
Withdrew: Early termination of the study000578

Outcome measures

PrimaryPercentage of Participants With American College of Rheumatology 20 (ACR20) Responses

ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale \[VAS\]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage
Percentage of Participants With American College of Rheumatology 20 (ACR20) Responses
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Percentage of Responders at Week 2422 (17.1 to 26.9)42.2 (36.4 to 48.1)47.9 (42.0 to 53.7)
Percentage of Responders at Week 4819.5 (14.8 to 24.2)48.7 (42.9 to 54.6)50.7 (44.9 to 56.5)
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 20.4 · 95% CI 12.8 to 27.9
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 25.2 · 95% CI 17.7 to 32.7
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 29.1 · 95% CI 21.6 to 36.6
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 30.3 · 95% CI 22.8 to 37.7
SecondaryPercentage of Participants With a Major Clinical Response

Major clinical response was defined as achieving an ACR70 response and maintaining this response for a consecutive period of at least 6 months.

Time frame:
Week 48
Reported as:
Number · Percentage
Percentage of Participants With a Major Clinical Response
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Percentage of Participants With a Major Clinical Response1.8 (0.2 to 3.4)4.0 (1.7 to 6.3)5.7 (3.0 to 8.4)
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.1885 · Weighted difference: 2.1 · 95% CI -1.0 to 5.2
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.0330 · Weighted difference: 3.6 · 95% CI 0.3 to 6.8
SecondaryPercentage of Participants Achieving Disease Activity Score (DAS28) Remission

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage
Percentage of Participants Achieving Disease Activity Score (DAS28) Remission
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Percentage of Participants at Week 241.8 (0.2 to 3.4)5.8 (3.0 to 8.5)6.0 (3.3 to 8.8)
Percentage of Participants at Week 481.4 (0.0 to 2.8)11.9 (8.1 to 15.7)12.1 (8.3 to 15.9)
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.0175 · Weighted difference: 4.2 · 95% CI 0.7 to 7.6
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.0134 · Weighted difference: 4.3 · 95% CI 0.9 to 7.8
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 10.5 · 95% CI 6.2 to 14.8
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 10.5 · 95% CI 6.2 to 14.7
SecondaryChange in DAS28 From Baseline

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.

Time frame:
Weeks 24 and 48
Reported as:
Mean · Score on a scale
Change in DAS28 From Baseline
Score on a scalePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Baseline6.50 ± 1.0146.47 ± 1.2176.44 ± 1.039
Week 24-0.99 ± 1.166-1.60 ± 1.307-1.91 ± 1.349
Week 48-1.13 ± 1.404-2.11 ± 1.348-2.38 ± 1.496
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Analysis of Variance · p = < 0.0001 · Adjusted mean difference: -0.6 · 95% CI -0.8 to -0.3
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Analysis of Variance · p = < 0.0001 · Adjusted mean difference: -0.9 · 95% CI -1.1 to -0.6
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Analysis of Variance · p = < 0.0001 · Adjusted mean difference: -0.9 · 95% CI -1.2 to -0.7
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Analysis of Variance · p = < 0.0001 · Adjusted mean difference: -1.2 · 95% CI -1.5 to -0.9
SecondaryPercentage of Participants With EULAR Response Rates of Good/ Moderate

The EULAR response rate was based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage
Percentage of Participants With EULAR Response Rates of Good/ Moderate
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Week 2431.454.261.0
Week 4824.958.860.3
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Proportional Odds Analysis · p = < 0.0001 · Odds ratio (or): 2.60 · 95% CI 1.85 to 3.66
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Proportional Odds Analysis · p = < 0.0001 · Odds ratio (or): 3.49 · 95% CI 2.49 to 4.91
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Proportional Odds Analysis · p = < 0.0001 · Odds ratio (or): 4.18 · 95% CI 2.93 to 5.96
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Proportional Odds Analysis · p = < 0.0001 · Odds ratio (or): 5.04 · 95% CI 3.54 to 7.18
SecondaryPercentage of Participants Achieving an ACR50 Response

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, Health Assessment Questionnaire with Disability Index (HAQ-DI), and C-Reactive Protein (CRP).

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage
Percentage of Participants Achieving an ACR50 Response
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Percentage of Participants at Week 247.9 (4.8 to 11.1)21.3 (16.5 to 26.1)24.8 (19.8 to 29.9)
Percentage of Participants at Week 489 (5.7 to 12.4)28.5 (23.2 to 33.8)30.9 (25.5 to 36.2)
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 13.2 · 95% CI 7.4 to 19.1
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 16.2 · 95% CI 10.2 to 22.1
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 19.3 · 95% CI 12.9 to 25.6
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 20.8 · 95% CI 14.5 to 27.1
SecondaryPercentage of Participants Achieving an ACR70 Response

ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, HAQ-DI and CRP.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage
Percentage of Participants Achieving an ACR70 Response
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Percentage of Participants at Week 242.9 (0.9 to 4.9)7.6 (4.5 to 10.7)9.9 (6.4 to 13.4)
Percentage of Participants at Week 484.3 (1.9 to 6.7)11.2 (7.5 to 14.9)18.1 (13.6 to 22.6)
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.0203 · Weighted difference: 4.6 · 95% CI 0.7 to 8.5
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.0014 · Weighted difference: 6.7 · 95% CI 2.6 to 10.8
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = 0.0042 · Weighted difference: 6.6 · 95% CI 2.1 to 11.2
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 13.4 · 95% CI 8.2 to 18.6
SecondaryPercentage of Participants With a Reduction in the HAQ-DI Score

Health Assessment Questionnaire - Disability Index (HAQ-DI): The Stanford Health Assessment Questionnaire disability index is a patient reported questionnaire specific for RA. It consists of 20 questions referring to eight component. Reduction in the HAQ-DI score of 0.25 units from baseline to weeks 24 and 48 represented a minimal clinically relevant improvement.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage
Percentage of Participants With a Reduction in the HAQ-DI Score
PercentagePlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARD
Percentage of Participants at Week 2432.9 (27.3 to 38.4)52.3 (46.5 to 58.2)58.5 (52.8 to 64.3)
Percentage of Participants at Week 4823.1 (18.1 to 28.1)50.5 (44.7 to 56.4)51.8 (45.9 to 57.6)
Statistical analysis
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 19.4 · 95% CI 11.3 to 27.5
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 24.7 · 95% CI 16.8 to 32.7
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 200 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 27.2 · 95% CI 19.5 to 34.9
  • Placebo x 2 IV + Non-Biologic DMARD vs Ocrelizumab 500 mg x 2 + Non-Biologic DMARD · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 27.6 · 95% CI 20.0 to 35.3

Adverse events

Collected over From Day 1 to Week 48 and Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo x 2 IV + Non-Biologic DMARD5/276 (1.8%)41/276 (14.9%)152/276 (55.1%)
Ocrelizumab 200 mg x 2 + Non-Biologic DMARD2/276 (0.7%)46/276 (16.7%)153/276 (55.4%)
Ocrelizumab 500 mg x 2 + Non-Biologic DMARD4/284 (1.4%)40/284 (14.1%)158/284 (55.6%)
Ocrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE)11/664 (1.7%)138/664 (20.8%)361/664 (54.4%)
Most frequent serious events
Showing 10 of 239
Most frequent serious events
EventPlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE)
Rheumatoid arthritisMusculoskeletal and connective tissue disorders7/2764/2764/2847/664
PneumoniaInfections and infestations5/2765/2761/28411/664
CellulitisInfections and infestations3/2760/2760/2841/664
Myocardial infarctionCardiac disorders1/2762/2761/2846/664
AnaemiaBlood and lymphatic system disorders2/2760/2760/2841/664
Angina pectorisCardiac disorders1/2762/2761/2841/664
BronchitisInfections and infestations2/2760/2760/2841/664
Pulmonary tuberculosisInfections and infestations0/2762/2760/2840/664
Tendon ruptureInjury, poisoning and procedural complications2/2760/2761/2841/664
OsteoarthritisMusculoskeletal and connective tissue disorders2/2762/2761/2842/664
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 IV + Non-biologic DMARD (OLE)
Infusion related reactionInjury, poisoning and procedural complications25/27641/27641/284128/664
Upper respiratory tract infectionInfections and infestations36/27637/27645/28496/664
Urinary tract infectionInfections and infestations23/27619/27624/28478/664
NasopharyngitisInfections and infestations31/27628/27622/28469/664
BronchitisInfections and infestations19/27628/27622/28464/664
SinusitisInfections and infestations14/27613/27613/28453/664
HypertensionVascular disorders21/27618/27619/28444/664
InsomniaPsychiatric disorders12/2769/27616/2840/664
DarrhoeaGastrointestinal disorders10/27615/27615/2840/664
NauseaGastrointestinal disorders15/27611/27610/2840/664

Baseline characteristics

Intent-toTreat (ITT) All randomized participants who received any part of an infusion of study medication were included in the ITT analysis

Age, Continuous
Age, Continuous(years)Placebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDTotal
Mean54.1 ± 11.354.5 ± 11.253.8 ± 11.654.2 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDTotal
Female215214236665
Male626346171
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo x 2 IV + Non-Biologic DMARDOcrelizumab 200 mg x 2 + Non-Biologic DMARDOcrelizumab 500 mg x 2 + Non-Biologic DMARDTotal
American indian or Alaska native98926
Asian (Indian Subcontinent)1001
Asian (Other than Indian subcontinent)393838115
Black16181246
Native Hawaiian or other Pacific Islander0123
Other6111431
White206201207614
08

Study locations

266 sites
  • Pinnacle Research Group; Llc, Central
    Anniston, Alabama 36207, United States
  • Rheumatology Associates
    Birmingham, Alabama 35205, United States
  • Rheumatology Associates of North Alabama
    Huntsville, Alabama 35801, United States
  • Arizona Arthritis & Rheumatology Research, Pllc
    Mesa, Arizona 85202, United States
  • Arthrocare, Arthritis Care and Research, P.C.
    Mesa, Arizona 85208, United States
  • Catalina Pointe Clinical Research, Inc.
    Tucson, Arizona 85704, United States
  • Uni of Arizona Health Science Center; Dept of Rheumatology/Immunology
    Tucson, Arizona 85724, United States
  • CHI St. Vincent Medical Group Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Little Rock Diagnostic Clinic
    Little Rock, Arkansas 72205, United States
  • Allergy & Rheumatology Centre
    La Jolla, California 92037, United States
  • Private Practice
    Long Beach, California 90808, United States
  • Valerius Medical Group & Research Ctr of Greater Long Beach
    Los Alamitos, California 90720, United States
  • Uni of Southern California School of Medicine
    Los Angeles, California 90033, United States
  • Pacific Arthritis Care Center
    Los Angeles, California 90045, United States
  • Stanford Uni Medical Center; Divison of Rheumatology
    Palo Alto, California 94304, United States
  • Ucsd, Dept of Medicine; Rheumatology
    San Diego, California 92093, United States
  • San Diego Arthritis Med Clnc
    San Diego, California 92108, United States
  • East Bay Rheumatology
    San Leandro, California 94578, United States
  • Arthritis Treatment Center of South Bay
    Torrance, California 90505, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
    Colorado Springs, Colorado 80920, United States
  • Arthritis & Osteoporosis Center P.C.
    Camden, Connecticut 06510, United States
  • New England Research Associates
    Trumbull, Connecticut 06611, United States
  • Rheumatolgy Consultants of Deleware
    Lewes, Delaware 19958, United States
  • Javed Rheumatology Associates, Inc.
    Newark, Delaware 19713, United States
  • Arthritis & Rheumatism; Disease Specialities
    Aventura, Florida 33180, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Arthritis Center Palm Harbor
    Palm Harbor, Florida 34684, United States
  • Arthritis Rsrch of Florida, Inc.
    Palm Harbor, Florida 34684, United States
  • Sarasota Arthritis Center; Research Dept
    Sarasota, Florida 34239, United States
  • Center For Arthritis; Research Dept
    South Miami, Florida 33143, United States
  • SW Florida Clinical Research
    Tampa, Florida 33609, United States
  • Tampa General Hospital; Rheumatology Research Dept
    Tampa, Florida 33612, United States
  • Burnette & Silverfield, MDS
    Tampa, Florida 33614, United States
  • Florida Medical Center
    Zephyrhills, Florida 33540, United States
  • Atlanta Center For Clinical Research.
    Atlanta, Georgia 30342, United States
  • Csi Research, Inc.
    Cumming, Georgia 30041, United States
  • Marietta Rheumatology Associates, Pc
    Marietta, Georgia 30060, United States
  • Intermountain Orthopaedics
    Boise, Idaho 83702, United States
  • Coeur D'Alene Arthritis Clinic
    Coeur d'Alene, Idaho 83814, United States
  • Idaho Arthritis Center
    Meridian, Idaho 83642, United States
  • Uni of Chicago
    Chicago, Illinois 60637, United States
  • Evanston Northwestern Healthcare; Rheumatology
    Evanston, Illinois 60201, United States
  • Quad City Rheumatology, Sc
    Moline, Illinois 61265, United States
  • Illinois Bone & Joint Inst.
    Morton Grove, Illinois 60053, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Iu Outpatient Clinical Research Facility
    Indianapolis, Indiana 46202-5149, United States
  • Diagnostic Rheumatology & Research
    Indianapolis, Indiana 46227, United States
  • Medical Specialists Clinical Research Center
    Munster, Indiana 46321, United States
  • Physician'S Clinic of Iowa
    Cedar Rapids, Iowa 52401, United States
  • Uni of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Center For Arthritis & Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Bluegrass Comm Research, Inc.
    Lexington, Kentucky 40515, United States
  • Kentuckiana Center For Better Bone & Joint Healthx
    Louisville, Kentucky 40202, United States
  • Baton Rouge Clinic, Amc
    Baton Rouge, Louisiana 70808, United States
  • Johns Hopkins University; Department of Rheumatology
    Baltimore, Maryland 21224, United States
  • Center For Rheumatology & Bone Research
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Clinsite;Research Division of Integrated Health Associates
    Ann Arbor, Michigan 48106, United States
  • Rheumatology, P.C.; Medical Arts Building
    Kalamazoo, Michigan 49009, United States
  • Borgess Research Institute
    Kalamazoo, Michigan 49048, United States
  • Fiechtner Research Inc
    Lansing, Michigan 48910, United States
  • Office of Andrew Sulich, Md
    Saint Clair Shores, Michigan 48080, United States
  • St Luke's Whiteside Research
    Duluth, Minnesota 55805, United States
  • St. Mary'S Duluth Clinic Health System; Rheumatology Dept
    Duluth, Minnesota 55805, United States
  • St. Paul Rheumatology
    Eagan, Minnesota 55121, United States
  • Park Nicollet Inst. ; Rtrc
    Minneapolis, Minnesota 55416, United States
  • Jackson Arthritis Clinic
    Flowood, Mississippi 39232, United States
  • North Mississippi Medical Ctr; Internal Medicine Associates
    Tupelo, Mississippi 38802, United States
  • David S Rosenberg
    Florissant, Missouri 63031, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Physicians Group, LC DBA Rheumatology & Internal Medicine Associates
    Saint Louis, Missouri 63131, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • St. John'S Health System Inc.; St. John'S Medical Research
    Springfield, Missouri 65807, United States
  • Westroads Medical Group
    Omaha, Nebraska 68114, United States
  • Seacoast Arthritis and Osteoporosis Center
    Dover, New Hampshire 03820, United States
  • Nashua Rheumatology - Foundation Medical Partners
    Nashua, New Hampshire 03060, United States
  • Mark Fisher Md, Facr, Llc
    Haddon Heights, New Jersey 08035, United States
  • Arthritis Rheumatic & Back Disease Associates
    Voorhees, New Jersey 08043, United States
  • The Center of Rheumatology
    Albany, New York 12206, United States
  • Arthritis & Osteoporosis Center
    Brooklyn, New York 11201, United States
  • Southern Tier Arthritis & Rheumatism
    Olean, New York 14760, United States
  • Aair Research Center
    Rochester, New York 14618, United States
  • Andrew Porges Pc
    Roslyn, New York 11576, United States
  • Rheumatology Associates of Long Island
    Smithtown, New York 11787, United States
  • Asheville Arthritis & Osteoporosis Center, PA
    Asheville, North Carolina 28803, United States
  • Arthritis Associates
    Belmont, North Carolina 28012, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Carolina Bone & Joint P.A.
    Charlotte, North Carolina 28210, United States
  • Physicians East Pa
    Greenville, North Carolina 27834, United States
  • St. Alexius Medical Center; Arthritis Clinic
    Bismarck, North Dakota 58501, United States
  • Deaconess Arthritis Center; Rheumatic Disease Study Group
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Stat Research, Inc
    Dayton, Ohio 45402, United States
  • David Mandel Inc
    Mayfield, Ohio 44143, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Health Research of Oklahoma, Llc
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Center For Arthritis Therapy & Research
    Tulsa, Oklahoma 74104, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States

Showing the first 100 of 266 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Emery P, Rigby W, Tak PP, Dorner T, Olech E, Martin C, Millar L, Travers H, Fisheleva E. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014 Feb 3;9(2):e87379. doi: 10.1371/journal.pone.0087379. eCollection 2014. PubMed 24498318 ↗
  • Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham CO 3rd, Ashrafzadeh A, Travers H, Safa-Leathers S, Kumar S, Dummer W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012 Feb;64(2):360-70. doi: 10.1002/art.33353. PubMed 22389919 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2007 to primary completion in Jan 2010, 32 months.

Results were first posted in Aug 2019, 9 years 6 months after primary completion. A results delay was requested in Aug 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2007
First posted
May 22, 2007
StartActual
May 15, 2007
Primary completionActual
Jan 21, 2010
CompletionActual
May 14, 2018
Results delay requested
Aug 20, 2013
Results first posted
Aug 12, 2019
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00476996
Lead sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
May 22, 2007
Start date
May 15, 2007
Primary completion
Jan 21, 2010
Completion
May 14, 2018
Results posted
Aug 12, 2019
Last update
Aug 12, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion